Selective MAGL inhibitor (research)

Plain-language summaryIntrigue 50 / 100

JZL184 is the canonical research probe for blocking MAGL, the enzyme that breaks down the endocannabinoid 2-AG. It was developed in the Cravatt laboratory at Scripps and works by permanently inactivating the enzyme, which raises 2-AG levels and produces cannabinoid-like effects without direct receptor agonism. Animal work shows analgesic and anti-inflammatory activity, but a meaningful complication is that JZL184 also partially inhibits FAAH (about 300-fold MAGL preference), muddying interpretation of some early studies. Cleaner second-generation tools like KML29 have largely replaced it for definitive mechanism work. Not a clinical compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

The canonical covalent MAGL probe; indispensable for 2-AG signaling research but carries no clinical trajectory of its own

Look, JZL184 is one of those compounds where the story is almost entirely about what it lets you do at the bench rather than what it might eventually do in a person. Brian Cravatt’s group at Scripps published the original covalent piperidinyl-carbamate scaffold in 2009, and the compound has been the go-to MAGL inhibitor ever since. That’s roughly fifteen years of multi-lab use, which tells you something: the selectivity profile held up, the covalent mechanism turned out to be a feature rather than a liability for probe work, and nobody has made something clearly better for the specific task of irreversibly blocking MAGL while leaving FAAH intact.

The mechanism is genuinely elegant. JZL184 carbamoylates the active-site serine of MAGL, producing irreversible inactivation. The selectivity over FAAH runs about 300-fold, which is what lets investigators dissect the 2-AG arm of endocannabinoid signaling from the AEA arm without crossover noise. Thats critical: AEA and 2-AG occupy very different regulatory niches at CB1 synapses, and pharmacologically parsing them has been a long-standing methodological problem. JZL184 solved the MAGL side of that problem cleanly. The behavioral pharmacology that follows from MAGL inhibition is more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at higher doses), which reflects the higher tonic CB1 occupancy that comes from pooling 2-AG rather than AEA.

What we like here is the bench specificity. If you’re working on 2-AG-mediated retrograde signaling, CB1 synaptic plasticity, MAGL’s role in neuroinflammation, or the non-CB1 downstream targets of elevated 2-AG (GPR55, PPARs), JZL184 is probably already in your protocol. The replication record across labs is genuinely strong for a research tool compound. Papers out of Piomelli’s group, Bhatt’s group, and a long list of academic neuroscience labs have built on the Scripps scaffold without needing to re-validate the selectivity claims from scratch.

The limitations are real though. Novelty is low because the compound is mature; the research frontier using JZL184 is about what investigators do with it, not the compound itself. Translational signal is basically absent because JZL184 was never designed as a development candidate, and its irreversible mechanism creates tolerability concerns that have kept it out of clinical consideration. There is no human data and no active IND. The endocannabinoid axis it probes is extremely relevant to pain and neuroinflammation programs, but those programs are being run with next-generation reversible MAGL inhibitors like ABX-1431, not with JZL184. Honestly, that’s fine. JZL184’s job is to be the canonical probe, and it does that job very well. Score it accordingly.

Novelty: 38
Mechanism promise: 62
In-category differentiation: 72
Evidence quality: 62
Translational signal: 24
Research bench value: 78

Rationale JZL184 scores high on differentiation and bench value because it remains the reference-standard MAGL inhibitor after 15 years, with no serious competitor for clean irreversible 2-AG elevation in preclinical models; it scores low on novelty and translational signal because the compound itself is mature and has never entered human development, functioning purely as a tool rather than a drug candidate.

Selective MAGL inhibitor (research)

A covalent inhibitor of monoacylglycerol lipase (MAGL); the canonical research probe for elevating endogenous 2-AG.

Abstract

JZL184 (CAS 1101854-58-3; molecular formula C27H24F2N2O5; molecular weight 510.49) is a covalent piperidinyl-carbamate inhibitor of monoacylglycerol lipase (MAGL) developed by Cravatt and colleagues at Scripps. The compound carbamoylates the active-site serine of MAGL, producing irreversible enzyme inactivation. Selective for MAGL over FAAH (approximately 300-fold) and other serine hydrolases. Pharmacological consequence: elevation of endogenous 2-AG (the principal full-agonist endocannabinoid) without direct CB receptor agonism. Behavioral effects are more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at high dose), reflecting the higher tonic CB1 occupancy from elevated 2-AG. Used as the canonical MAGL inhibitor in academic neuroscience for studies of 2-AG signaling and CB1-mediated synaptic plasticity. No human clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-330Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Selective MAGL inhibitor (research)

JZL184

Abstract

Read the full monograph